US EditionNew federal screening guidance expands cervical cancer testing with an at-home HPV option
HRSA's updated guidance endorses FDA-approved at-home HPV self-testing covered by private insurers from 2027 to increase screening access and early cervical cancer detection.
- On Monday, the Department of Health and Human Services updated HRSA guidance to allow at-home HPV testing by prescription, with private insurers required to cover it starting January 1, 2027.
- Amid falling screening rates since 2021, HRSA aims to reach people missed by screening and build on the last 50 years' progress where incidence and deaths fell by more than 50%.
- Regulatory clearances now permit self-collection both in clinics and, for one device, at home; HRSA recommends only FDA-approved self-collection tests, which can be clinician- or patient-collected.
- Engels said the updates will improve screening rates and save lives, requiring private insurers to cover follow-up testing without cost-sharing, while CDC data show over 90% five-year survival with early detection.
- The American Cancer Society's updated guidance notes recommend primary HPV testing from age 25 and at-home testing every three years, while rising rates in women in their 30s and 40s and about 13,000 annual U.S. cases highlight ongoing risks.
17 Articles
17 Articles
Federal guidelines for cervical cancer screening now include self-collection option
HHS’s Health Resources and Services Administration released updated guidance for cervical cancer screening, which includes a new option for average-risk women to self-collect vaginal samples for HPV testing.The guidance, published in JAMA, “is designed to help close the screening gap by expanding access and reducing cost barriers,” HRSA told Healio.
HRSA updates cervical cancer screening guidelines
The Health Resources and Services Administration yesterday announced updated cervical cancer screening guidelines, including optional self-collection of samples for screening. The guidelines also recommend high-risk human papillomavirus testing for average-risk women ages 30-65, and pap smears for average-risk women ages 21-29. HRSA said the guidelines also include new language requiring most insurance plans to cover any additional testing neces…
Coverage Details
Bias Distribution
- 57% of the sources are Center
Factuality
To view factuality data please Upgrade to Premium
